FDA blesses Merck's grass pollen allergy drug
This article was originally published in Scrip
Executive Summary
Merck won approval from the FDA on 14 April to market its allergy sublingual immunotherapy tablet Grastek against Phleum pratense, or Timothy grass pollen – one of the most common grasses in the US, which has been demonstrated to be cross-reactive with other grasses, including sweet vernal, orchard, perennial rye, Kentucky blue, meadow fescue and redtop.